Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres, L. Puig, Ronald Vender, Charles Lynde, Stefano Piaserico, J.M. Carrascosa, Paolo Gisondi, E. Daudén, Curdin Conrad, Pedro Mendes‐Bastos, Paulo Ferreira, Luíz Leite, Justin D. Lu, Joana Valério, Manfredo Bruni, Francesco Messina, Alessia Nidegger, Mar Llamas‐Velasco, E. del Alcázar, Asfandyar Mufti, Kyra White, Giacomo Caldarola, Laetitia Teixeira, Paolo Romanelli, K. Desai, Spyridon Gkalpakiotis, Marco Romanelli, Jensen Yeung, Miguel Nogueira, Andrea Chiricozzi
Topics & Concepts
MedicineSecukinumabIxekizumabUstekinumabPsoriatic arthritisInternal medicineRetrospective cohort studyPsoriasisHazard ratioProportional hazards modelOncologyDermatologyAdalimumabConfidence intervalDiseasePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases